AU4090589A - The use of plasminogen activator inhibitor (pai-2) for immunosuppression - Google Patents

The use of plasminogen activator inhibitor (pai-2) for immunosuppression

Info

Publication number
AU4090589A
AU4090589A AU40905/89A AU4090589A AU4090589A AU 4090589 A AU4090589 A AU 4090589A AU 40905/89 A AU40905/89 A AU 40905/89A AU 4090589 A AU4090589 A AU 4090589A AU 4090589 A AU4090589 A AU 4090589A
Authority
AU
Australia
Prior art keywords
pai
immunosuppression
plasminogen activator
activator inhibitor
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU40905/89A
Other versions
AU616555B2 (en
Inventor
Norbert Heimburger
Hans Ulrich Schorlemmer
Thomas Stief
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of AU4090589A publication Critical patent/AU4090589A/en
Application granted granted Critical
Publication of AU616555B2 publication Critical patent/AU616555B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The possibility of using plasminogen activator inhibitor (PAI-2) for producing a medicament for immunosuppression is described. Also described is a medicament containing PAI-2 and an ornithine decarboxylase inhibitor.
AU40905/89A 1988-08-31 1989-08-30 The use of plasminogen activator inhibitor (pai-2) for immunosuppression Ceased AU616555B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3829523A DE3829523A1 (en) 1988-08-31 1988-08-31 USE OF PLASMINOGEN ACTIVATOR INHIBITOR (PAI-2) FOR IMMUNE SUPPRESSION
DE3829523 1988-08-31

Publications (2)

Publication Number Publication Date
AU4090589A true AU4090589A (en) 1990-03-08
AU616555B2 AU616555B2 (en) 1991-10-31

Family

ID=6361973

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40905/89A Ceased AU616555B2 (en) 1988-08-31 1989-08-30 The use of plasminogen activator inhibitor (pai-2) for immunosuppression

Country Status (9)

Country Link
EP (1) EP0356945B1 (en)
JP (1) JPH02108633A (en)
KR (1) KR900002791A (en)
AT (1) ATE97576T1 (en)
AU (1) AU616555B2 (en)
DE (2) DE3829523A1 (en)
DK (1) DK428089A (en)
ES (1) ES2061842T3 (en)
PT (1) PT91584B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049887A1 (en) * 1998-04-01 1999-10-07 Biotech Australia Pty. Limited Use of protease inhibitors for treating skin wounds
WO2000007620A1 (en) * 1998-08-05 2000-02-17 Biotech Australia Pty. Ltd. Protease inhibitors for use in the treatment of psoriasis

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4214215A1 (en) * 1992-04-30 1993-11-04 Behringwerke Ag USE OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATING INFLAMMATION
EP1066834A3 (en) * 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmaceutical compositions comprising a phagocyte-modulating agent
AU1123001A (en) 1999-10-27 2001-05-08 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
AUPQ380699A0 (en) * 1999-11-02 1999-11-25 Biotech Australia Pty Limited Protease inhibitors as modulators of periodontal wound healing
CA2423313A1 (en) 2000-09-29 2002-04-04 Z. Robert Zhong Methods of treating inflammatory and immune reactions and compositions therefor
KR100550385B1 (en) * 2002-11-11 2006-02-08 메타볼랩(주) Inhibitor from Adhesion between Candida and Its Host Cell Comprising Transglutaminase as Active Ingredient
JP4578067B2 (en) * 2003-06-06 2010-11-10 宏 清水 Topical pharmaceutical composition
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
WO1986003973A1 (en) * 1985-01-14 1986-07-17 Terumo Kabushiki Kaisha Fibrinophilic urokinase complex and process for its preparation
DE3713272A1 (en) * 1987-04-18 1988-11-03 Behringwerke Ag Plasminogen activator inhibitor type 2 (PAI-2)
DE3829524A1 (en) * 1988-08-31 1990-03-01 Behringwerke Ag USE OF TRANSGLUTAMINASES AS IMMUNE SUPPRESSIVA

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049887A1 (en) * 1998-04-01 1999-10-07 Biotech Australia Pty. Limited Use of protease inhibitors for treating skin wounds
WO2000007620A1 (en) * 1998-08-05 2000-02-17 Biotech Australia Pty. Ltd. Protease inhibitors for use in the treatment of psoriasis

Also Published As

Publication number Publication date
DE3829523A1 (en) 1990-03-01
DK428089A (en) 1990-03-01
ATE97576T1 (en) 1993-12-15
KR900002791A (en) 1990-03-23
EP0356945A3 (en) 1991-07-31
PT91584B (en) 1995-05-31
EP0356945B1 (en) 1993-11-24
DE58906241D1 (en) 1994-01-05
DK428089D0 (en) 1989-08-30
AU616555B2 (en) 1991-10-31
JPH02108633A (en) 1990-04-20
PT91584A (en) 1990-03-08
EP0356945A2 (en) 1990-03-07
ES2061842T3 (en) 1994-12-16

Similar Documents

Publication Publication Date Title
AU4135289A (en) Pharmaceutically active combination
EP0727210A3 (en) Analgesic agent and its use
MY106263A (en) Method for the treatment or prevention of intrinsically aged skin with retinoids
AU4090589A (en) The use of plasminogen activator inhibitor (pai-2) for immunosuppression
AU4090489A (en) The use of transglutaminases as immunosuppressants
AU6772387A (en) Treatment of thrombosis with fibrinolytic agents and prostacyclines
IL91131A (en) Method of preserving ophthalmic solutions using a hydrogen peroxide source and compositions therefor
ES2099021A1 (en) Pharmaceutical composition having analgesic activity
EP0328957A3 (en) Mixture of a thrombolytically acting and an antithrombolytically acting substance
AU569102B2 (en) Monohydroxy-benzoyl peroxide
NZ230327A (en) Synergistic combination of t-pa and activated protein c (apc)
AU1830592A (en) A method of preparing activated protein c
EP0350738A3 (en) (s)-emopamil for use in the treatment of migraine
CA2105888A1 (en) Use of a direct thrombin inhibitor in the production of a drug presenting a thrombolytic activity
AU6243186A (en) A pharmaceutical composition for the treatment of high blood pressure
AU5642794A (en) Agent for preventing adhesion of thallium 201 to container
AU7719491A (en) Therapeutic compound
CA2017636A1 (en) Derivative of tissue-type plasminogen activator
AU612562B2 (en) A composition comprising a plasmin inhibitor and a plasminogen activator for the treatment of thrombosis
AU609337B2 (en) Tissue plasminogen activator (t-pa) muteins and processes for the preparation thereof
TW360538B (en) Pharmaceutical composition containing 4'-iodo-4'-deoxydoxorubicin for treatment of amyloidosis